PTC Therapeutics Inc (PTCT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stuart W. Peltz
Employees:
1,410
100 CORPORATE COURT, SOUTH PLAINFIELD, NJ 07080-2449
9082227000

PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.

Data derived from most recent annual or quarterly report
Market Cap 1.89 Billion Shares Outstanding75.345 Million Avg 30-day Volume 960.748 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.76
Price to Revenue2.1163 Debt to Equity-0.8545 EBITDA-422.604 Million
Price to Book Value0.0 Operating Margin-80.8916 Enterprise Value1.968 Billion
Current Ratio1.098 EPS Growth-0.158 Quick Ratio0.936
1 Yr BETA 1.1898 52-week High/Low 59.84 / 17.53 Profit Margin-80.3956
Operating Cash Flow Growth13.6546 Free Cash Flow to Firm (FCFF) TTM -292.103 Million Free Cash Flow to Equity (FCFE) TTM-471.72 Million
Altman Z-Score-3.8934
Earnings Report2024-02-20
View SEC Filings from PTCT instead.

View recent insider trading info

PTC Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PTCT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PTCT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-08 by YOUNG ALETHIA
  • 4: filed on 2023-07-17 by GRAVIER PIERRE
  • 3: filed on 2023-07-17 by GRAVIER PIERRE
  • 3: filed on 2023-06-13 by GOLDEN LEE SCOTT
  • 4: filed on 2023-06-09 by SCHMERTZLER MICHAEL
  • 4: filed on 2023-06-07 by BELL WILLIAM F. JR.
  • 3: filed on 2023-06-07 by BELL WILLIAM F. JR.
  • 4: filed on 2023-05-24 by REEVE EMMA
  • 4: filed on 2023-05-23 by PAUWELS ERIC
  • 4: filed on 2023-05-19 by PAUWELS ERIC

    • Events (8k)

  • 8-K: filed on 2023-10-26:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-19:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-28:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-15:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-19:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-21:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-23:
  • 144: filed on 2023-05-22:
  • 144: filed on 2023-05-22:
  • 144: filed on 2023-05-19:
  • 144: filed on 2023-05-18:
  • 144: filed on 2023-05-17:
  • 144: filed on 2023-05-11:
  • 144: filed on 2023-04-21:
  • 144: filed on 2023-04-21:
  • 144: filed on 2023-04-18:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    YOUNG ALETHIA

    • Director
    		 9,067 2023-09-06 2

    GRAVIER PIERRE CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-07-13 2

    SCHMERTZLER MICHAEL

    • Director
    		 116,766 2023-06-07 2

    GOLDEN LEE SCOTT CHIEF MEDICAL OFFICER

    • Officer
    		 39,286 2023-06-06 1

    BELL WILLIAM F. JR.

    • Director
    		 0 2023-06-06 2

    REEVE EMMA

    • Director
    		 7,200 2023-05-22 3

    PAUWELS ERIC CHIEF BUSINESS OFFICER

    • Officer
    		 47,553 2023-05-19 8

    JACOBSON ALLAN STEVEN

    • Director
    		 12,348 2023-05-11 2

    UTTER CHRISTINE MARIE SVP, FINANCE & CAO

    • Officer
    		 38,059 2023-04-21 7

    KLEIN MATTHEW B. CHIEF EXECUTIVE OFFICER

    • Officer
    		 102,645 2023-04-18 4

    SOUTHWELL DAVID P

    • Director
    		 10,500 2023-04-17 4

    BOULDING MARK ELLIOTT EXEC. VP AND CLO

    • Officer
    		 75,378 2023-04-17 5

    HILL EMILY LUISA CHIEF FINANCIAL OFFICER

    • Officer
    		 38,925 2023-03-27 6

    ALMSTEAD NEIL GREGORY CHIEF TECHNICAL OPS OFFICER

    • Officer
    		 67,208 2023-01-31 5

    PELTZ STUART WALTER CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 221,865 2023-01-31 5

    STEELE GLENN JR MD PHD

    • Director
    		 20,500 2023-01-05 1

    ZELDIS JEROME B

    • Director
    		 20,500 2023-01-05 1

    OKEY STEPHANIE

    • Director
    		 15,867 2023-01-05 1

    SMITH MARY L.

    • Director
    		 19,813 2023-01-05 1

    SVORONOS DAWN

    • Director
    		 29,017 2022-06-09 0

    SOUZA MARCIO CHIEF OPERATING OFFICER

    • Officer
    		 6,744 2020-02-10 0

    ROTHERA MARK CHIEF COMMERCIAL OFFICER

    • Officer
    		 42,955 2017-05-24 0

    KOVACS SHANE WILLIAM CHARLES CHIEF FINANCIAL OFFICER

    • Officer
    		 37,850 2017-05-09 0

    COMPLETE PHARMA HOLDINGS II, LLC

    • 10% Owner
    		 No longer subject to file 2017-04-28 0

    RENAUD RONALD C JR

    • Director
    		 0 2017-01-03 0

    KOPPEL ADAM

    • Director
    		 0 2017-01-03 0

    MCDONOUGH CAMERON GEOFFREY

    • Director
    		 0 2017-01-03 0

    ONG TUYEN CHIEF MEDICAL OFFICER

    • Officer
    		 6,000 2017-01-03 0

    SPIEGEL ROBERT J. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-01-04 0

    ALDRICH RICHARD

    • Director
    		 No longer subject to file 2015-06-08 0

    KRANDA MICHAEL L

    • Director
    		 2,242 2015-03-16 0

    HIRAWAT CLAUDIA DE OLIVEIRA RIBEIRO PRESIDENT

    • Officer
    		 No longer subject to file 2015-01-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PTC THERAPEUTICS INC PTCT 2023-12-05 16:45:04 UTC 5.0685 0.2515 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-05 16:15:04 UTC 5.0685 0.2515 2400000
    PTC THERAPEUTICS INC PTCT 2023-12-05 15:45:04 UTC 5.0685 0.2515 2400000
    PTC THERAPEUTICS INC PTCT 2023-12-05 15:15:05 UTC 5.0685 0.2515 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-05 14:45:03 UTC 5.0419 0.2781 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-05 14:15:04 UTC 5.0419 0.2781 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-05 13:45:04 UTC 5.0642 0.2558 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-05 13:15:04 UTC 5.0642 0.2558 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-05 12:45:05 UTC 5.0642 0.2558 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 22:15:04 UTC 5.0539 0.2661 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 21:45:03 UTC 5.0539 0.2661 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 21:15:03 UTC 5.0539 0.2661 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 20:45:04 UTC 5.0539 0.2661 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 20:15:05 UTC 5.0539 0.2661 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 19:45:03 UTC 5.0539 0.2661 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 19:15:04 UTC 5.0565 0.2635 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 18:45:04 UTC 5.0565 0.2635 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 18:15:05 UTC 5.0565 0.2635 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 17:45:03 UTC 5.0592 0.2608 2300000
    PTC THERAPEUTICS INC PTCT 2023-12-04 17:15:04 UTC 5.0592 0.2608 2300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund PTCT -491.0 shares, $-23582.73 2019-12-31 N-PORT
    FundVantage Trust- Gotham Enhanced Index Plus Fund PTCT -19.0 shares, $-847.59 2020-03-31 N-PORT
    FundVantage Trust- Gotham Master Neutral Fund PTCT -143.0 shares, $-6685.25 2020-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund PTCT -47.0 shares, $-2096.67 2020-03-31 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund PTCT -69.0 shares, $-2633.73 2022-12-30 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund PTCT -71.0 shares, $-2864.14 2023-07-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments